Tag: DES

paclitaxel

Meta-analysis finds a higher risk of death in the long term...

New data, just published in the Journal of the American Heart Association (JAHA), suggest that there is an increased risk of death at two...

Data from multiple studies support concept of low metal burden therapies...

Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce restenosis rates, according to results from various Biotronik studies...

Eluvia paclitaxel-eluting vascular stent system demonstrates promising three-year freedom from revascularisation

The three-year results from the MAJESTIC trial for Boston Scientific’s Eluvia paclitaxel-eluting vascular stent system at the Cardiovascular and Interventional Radiological Society of Europe...

Alvimedica obtains injunction by German court against sales of Microport drug-eluting...

The Court of Dusseldorf, Germany, has recognised in full the CID-Alvimedica rights on intellectual properties regarding the principles and related technology on drug release...

Akesys and Elixir announce first human implant of the Prava bioresorbable...

Akesys Medical has announced their first clinical trial and successful implant of the Prava sirolimus-eluting bioresorbable peripheral scaffold system for the treatment of blockage...

Promising findings for novel drug-eluting peripheral stent

A new animal study, presented at EuroPCR (17–20 May, Paris), indicates that a novel, fluoropolymer-coated, self-expanding, paclitaxel-eluting peripheral stent (Eluvia, Boston Scientific) is associated...